Holen Sie sich die Stockscreener-App
192.26
6.26%
-12.27
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt BIIB?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$204.53
Offen:
$200.25
24-Stunden-Volumen:
2.07M
Relative Volume:
1.82
Marktkapitalisierung:
$28.38B
Einnahmen:
$9.60B
Nettoeinkommen (Verlust:
$1.37B
KGV:
20.63
EPS:
9.3182
Netto-Cashflow:
$2.32B
1W Leistung:
+0.18%
1M Leistung:
+7.13%
6M Leistung:
+14.43%
1J Leistung:
+59.28%
1-Tages-Spanne:
$191.05
$205.00
1-Wochen-Bereich:
$189.50
$205.97
52-Wochen-Spanne:
$119.18
$205.97
Biogen Inc Stock (BIIB) Company Profile
Firmenname
Biogen Inc
Sektor
Telefon
(781) 464-2000
Adresse
225 BINNEY STREET, CAMBRIDGE, MA
Compare BIIB vs LLY, JNJ, ABBV, AZN, NVS
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BIIB
Biogen Inc
|
192.21 | 30.20B | 9.60B | 1.37B | 2.32B | 9.3182 |
LLY
Lilly Eli Co
|
1,006.60 | 905.79B | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
230.13 | 554.67B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
210.93 | 368.38B | 62.82B | 3.60B | 19.98B | 2.0274 |
AZN
Astrazeneca Plc
|
185.56 | 291.13B | 60.48B | 10.40B | 8.05B | 3.3297 |
NVS
Novartis Ag Adr
|
150.49 | 285.74B | 54.66B | 13.58B | 16.05B | 7.0171 |
Biogen Inc Stock (BIIB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-22 | Hochstufung | UBS | Neutral → Buy |
| 2026-04-20 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2026-04-14 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2026-02-20 | Eingeleitet | Barclays | Equal Weight |
| 2026-02-09 | Bestätigt | H.C. Wainwright | Buy |
| 2026-01-07 | Fortgesetzt | UBS | Neutral |
| 2025-12-10 | Herabstufung | HSBC Securities | Hold → Reduce |
| 2025-11-06 | Hochstufung | Stifel | Hold → Buy |
| 2025-09-25 | Eingeleitet | Jefferies | Buy |
| 2025-07-21 | Fortgesetzt | Truist | Hold |
| 2025-04-28 | Herabstufung | HSBC Securities | Buy → Hold |
| 2025-04-04 | Herabstufung | Argus | Buy → Hold |
| 2025-02-11 | Eingeleitet | Bernstein | Mkt Perform |
| 2025-01-02 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2024-12-20 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-16 | Herabstufung | Stifel | Buy → Hold |
| 2024-12-10 | Fortgesetzt | BofA Securities | Neutral |
| 2024-12-09 | Herabstufung | Jefferies | Buy → Hold |
| 2024-11-18 | Herabstufung | Needham | Buy → Hold |
| 2024-11-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2024-11-14 | Eingeleitet | Citigroup | Neutral |
| 2024-10-31 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-10-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2024-02-14 | Bestätigt | Needham | Buy |
| 2024-02-14 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-01-24 | Herabstufung | UBS | Buy → Neutral |
| 2023-12-20 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2023-12-07 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2023-09-06 | Eingeleitet | HSBC Securities | Buy |
| 2023-07-27 | Eingeleitet | Scotiabank | Sector Outperform |
| 2023-07-24 | Bestätigt | UBS | Buy |
| 2023-05-01 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-04-17 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-10-26 | Hochstufung | Goldman | Neutral → Buy |
| 2022-10-13 | Hochstufung | Stifel | Hold → Buy |
| 2022-10-07 | Hochstufung | Argus | Hold → Buy |
| 2022-09-28 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2022-09-28 | Hochstufung | Mizuho | Neutral → Buy |
| 2022-09-28 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2022-04-18 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2022-03-08 | Herabstufung | Stifel | Buy → Hold |
| 2022-03-03 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-02-04 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-04 | Bestätigt | Barclays | Equal Weight |
| 2022-02-04 | Bestätigt | BofA Securities | Neutral |
| 2022-02-04 | Bestätigt | Cowen | Outperform |
| 2022-02-04 | Bestätigt | Morgan Stanley | Overweight |
| 2022-02-04 | Bestätigt | Needham | Buy |
| 2022-02-04 | Bestätigt | Oppenheimer | Outperform |
| 2022-02-04 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2022-02-04 | Bestätigt | Robert W. Baird | Neutral |
| 2022-02-04 | Bestätigt | Wedbush | Neutral |
| 2022-02-04 | Bestätigt | Wells Fargo | Equal Weight |
| 2022-02-04 | Bestätigt | Wolfe Research | Peer Perform |
| 2022-01-13 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-01-12 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-12-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2021-12-06 | Eingeleitet | Goldman | Neutral |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-09-23 | Eingeleitet | Needham | Buy |
| 2021-06-18 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-06-14 | Bestätigt | Truist | Buy |
| 2021-06-11 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2021-06-10 | Hochstufung | UBS | Neutral → Buy |
| 2021-06-08 | Hochstufung | Atlantic Equities | Underweight → Neutral |
| 2021-06-08 | Bestätigt | Barclays | Equal Weight |
| 2021-06-08 | Hochstufung | Citigroup | Sell → Neutral |
| 2021-06-08 | Bestätigt | H.C. Wainwright | Buy |
| 2021-06-08 | Bestätigt | Jefferies | Buy |
| 2021-06-08 | Bestätigt | Morgan Stanley | Overweight |
| 2021-06-08 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2021-06-08 | Hochstufung | Robert W. Baird | Underperform → Neutral |
| 2021-06-08 | Bestätigt | Stifel | Buy |
| 2021-06-08 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2021-06-07 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2021-06-07 | Hochstufung | Cowen | Market Perform → Outperform |
| 2021-06-07 | Hochstufung | Raymond James | Underperform → Mkt Perform |
| 2021-02-05 | Herabstufung | DZ Bank | Buy → Hold |
| 2021-01-29 | Hochstufung | Stifel | Hold → Buy |
| 2020-11-10 | Hochstufung | DZ Bank | Hold → Buy |
| 2020-11-09 | Herabstufung | Atlantic Equities | Neutral → Underweight |
| 2020-11-09 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2020-11-09 | Herabstufung | Cowen | Outperform → Market Perform |
| 2020-11-09 | Bestätigt | H.C. Wainwright | Buy |
| 2020-11-04 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2020-11-04 | Hochstufung | Jefferies | Hold → Buy |
| 2020-11-04 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2020-10-28 | Eingeleitet | UBS | Neutral |
| 2020-07-27 | Hochstufung | Morgan Stanley | Underweight → Overweight |
| 2020-06-22 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2020-06-22 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2020-06-09 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2020-04-23 | Herabstufung | Citigroup | Neutral → Sell |
| 2020-04-23 | Herabstufung | Raymond James | Mkt Perform → Underperform |
| 2020-03-31 | Eingeleitet | Wolfe Research | Peer Perform |
| 2020-02-27 | Eingeleitet | Barclays | Overweight |
| 2020-01-27 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2019-12-13 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2019-12-02 | Herabstufung | Robert W. Baird | Neutral → Underperform |
Alle ansehen
Biogen Inc Aktie (BIIB) Neueste Nachrichten
Biogen Inc. on Pace for Largest Percent Decrease Since April 2025 -- Data Talk - Moomoo
Oligonucleotides Clinical Trial Drug Development Pipeline Expands with Contributions from 200+ Key Companies | DelveInsight - GlobeNewswire Inc.
Oppenheimer Raises Biogen Price Target to $300 From $275, Maintains Outperform Rating - marketscreener.com
Biogen to advance experimental Alzheimer's drug despite mid-stage trial miss - Reuters
Biogen’s SKYCLARYS Formulation Study: What a New Liquid Tablet Could Mean for BIIB Investors - TipRanks
Biogen Inc. (BIIB) Completes Acquisition of Apellis Pharmaceuticals - GuruFocus
Why Is Biogen Stock Falling Thursday? - Benzinga
Biogen Inc stock (US09062X1037): Recent developments and market position - AD HOC NEWS
Biogen Completes Acquisition of Apellis Pharmaceuticals, Expanding Portfolio with EMPAVELI and SYFOVRE for Growth in Nephrology and Ophthalmology 1 - Minichart
Biogen slides 3.9% as investors digest mixed Alzheimer’s tau data alongside Apellis deal close - Quiver Quantitative
Apellis Pharmaceuticals Announces Merger With Biogen, Delisting from Nasdaq, and Convertible Notes Repurchase/Conversion Options - Minichart
Jefferies reiterates Biogen stock rating on Alzheimer’s drug data - Investing.com
Biogen Completes Apellis Acquisition to Strengthen Growth - TipRanks
Apellis Completes Biogen Merger and Goes Private - TipRanks
Biogen stock maintains Outperform at Mizuho after trial results By Investing.com - Investing.com Canada
Biogen Completes Acquisition of Apellis Pharmaceuticals - Intellectia AI
Wolfe Research reiterates Peerperform on Biogen stock after trial miss By Investing.com - Investing.com Canada
Biogen (APLS) closes Apellis buyout at $41 per share plus CVRs and delists stock - Stock Titan
Biogen Finalizes Apellis CVR Terms (Up To $4) And Secures $2 Billion Term Loan Facilities - TradingView
Biogen (BIIB) closes $5.3B Apellis deal, adds EMPAVELI and SYFOVRE growth - Stock Titan
Biogen stock gains as Stifel maintains Buy on tau drug progress - Investing.com
Biogen to merge Apellis (NASDAQ: APLS) after tender offer closes - Stock Titan
Biogen reports phase 2 Alzheimer’s drug trial results - Investing.com
Apellis (APLS) tendered 82.4% of shares; Biogen to close merger May 14, 2026 - Stock Titan
Biogen posts trial data for Alzheimer’s drug (BIIB:NASDAQ) - Seeking Alpha
Biogen’s tau-targeting Alzheimer’s drug posts mixed results in mid-stage study - statnews.com
Biogen reports phase 2 Alzheimer’s drug trial results By Investing.com - Investing.com Canada
Ionis partner Biogen announces topline results from Phase 2 CELIA study of diranersen (BIIB080): first study to show reduction in tau pathology and cognitive benefit in patients with early Alzheimer’s disease - Business Wire
Topline Results from Phase 2 CELIA Study of Diranersen (BIIB080): First Study to Show Reduction in Tau Pathology and Cognitive Benefit in Patients with Early Alzheimer’s Disease - Biogen
Biogen Advances Alzheimer’s Drug on Suggestion of Benefit - Bloomberg.com
Biogen stock (US09062X1037): Hits 52-week high at $202.64 - AD HOC NEWS
Biogen stock hits 52-week high at $202.64 By Investing.com - Investing.com Nigeria
Biogen stock hits 52-week high at $202.64 - Investing.com
Biogen Inc (BIIB) Shares Surge 3.1% -- What GF Score of 77 Tells Investors - GuruFocus
Biogen Inc. stock (US09062X1037): Q1 milestone payment amid partner C4 Therapeutics earnings - AD HOC NEWS
Biogen Inc stock (US09062X1037): Latest developments and business overview - AD HOC NEWS
Biogen (NASDAQ: APLS) clears HSR waiting period for $41 Apellis tender - Stock Titan
Is Biogen Inc. (BIIB) one of the Best Biotech Stocks to Invest In According to Billionaire Steve Cohen? - Yahoo Finance
Should FDA’s LEQEMBI IQLIK Review Delay Reshape How Biogen (BIIB) Investors View Alzheimer’s Strategy? - simplywall.st
Lecanemab Injection Market Report 2026: Increasing Adoption of Monoclonal Antibody Therapies and Rising Focus on Early Alzheimer's Intervention - GlobeNewswire Inc.
Biogen Inc. stock (US09062X1037): Q1 earnings beat but guidance cut weighs on sentiment - AD HOC NEWS
Biogen to Participate in the Bank of America Securities 2026 Health Care Conference - Moomoo
symbol__ Stock Quote Price and Forecast - CNN
Biogen Stock Gains Despite Extended FDA Review For Alzheimer's Therapy - Benzinga
Biogen, Eisai hit with 3-month delay for starting SubQ Alzheimer’s therapy - BioSpace
FDA pushes back weekly Alzheimer's shot decision to Aug. 24 - Stock Titan
FDA extends review period for Eisai, Biogen Alzheimer’s drug - Investing.com
Eisai and Biogen Announce FDA Extension for LEQEMBI IQLIK Review for Early Alzheimer's Disease Treatment - Quiver Quantitative
FDA extends review period for Eisai, Biogen Alzheimer’s drug By Investing.com - Investing.com Nigeria
Update on FDA Priority Review of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection as a Starting Dose for Early Alzheimer’s Disease - Biogen
Eisai Co., Ltd. and Biogen Inc. Update on Fda Priority Review of Leqembi Iqlik (Lecanemab-Irmb) Subcutaneous Injection as A Starting Dose for Early Alzheimer's Disease - marketscreener.com
Finanzdaten der Biogen Inc-Aktie (BIIB)
Umsatz
Nettogewinn
Free Cashflow
ENV
Biogen Inc-Aktie (BIIB) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Godbout Sean | Chief Accounting Officer |
Apr 01 '26 |
Option Exercise |
0.00 |
181 |
0 |
1,396 |
| Murphy Nicole | Head of Pharm Ops and Tech |
Feb 12 '26 |
Buy |
195.03 |
3 |
585 |
19,611 |
| Viehbacher Christopher | President and CEO |
Feb 06 '26 |
Option Exercise |
0.00 |
24,461 |
0 |
36,548 |
| Singhal Priya | Head of Development |
Feb 06 '26 |
Option Exercise |
0.00 |
6,900 |
0 |
12,115 |
| Singhal Priya | Head of Development |
Feb 09 '26 |
Sale |
199.83 |
2,660 |
531,548 |
8,043 |
| Murphy Nicole | Head of Pharm Ops and Tech |
Feb 06 '26 |
Option Exercise |
0.00 |
8,725 |
0 |
21,016 |
| Kramer Robin | Chief Financial Officer |
Feb 06 '26 |
Option Exercise |
0.00 |
5,003 |
0 |
12,535 |
| Keeney Adam | Head of Corporate Development |
Feb 06 '26 |
Option Exercise |
0.00 |
5,080 |
0 |
6,875 |
| Izzar Rachid | Head of Global Product Strat. |
Feb 06 '26 |
Option Exercise |
0.00 |
6,889 |
0 |
11,786 |
| Grogan Jane | Head of Research |
Feb 06 '26 |
Option Exercise |
0.00 |
3,258 |
0 |
4,642 |
0.66%
0.07%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):